Skip to main content
Elsevier

Pioneering Precision in Cancer Treatment through 3D Bioprinting

  • 1st Edition - February 10, 2027
  • Latest edition
  • Editors: Anand Krishnan, Mamello Sekhoacha, Parks Makhoahle, Arun Kumar Singh
  • Language: English

Pioneering Precision in Cancer Treatment through 3D Bioprinting explores the transformative impact of 3D bioprinting on cancer therapy. This groundbreaking book examines innova… Read more

Description

Pioneering Precision in Cancer Treatment through 3D Bioprinting explores the transformative impact of 3D bioprinting on cancer therapy. This groundbreaking book examines innovative techniques revolutionizing cancer care, from creating patient-specific tumor models to accelerating drug discovery and enabling personalized treatments. It offers a comprehensive look at how 3D bioprinting is reshaping oncology. The book details the creation of intricate tumor models that mimic the in vivo environment, enabling precise drug testing and individualized treatment plans. It highlights 3D bioprinting's role in drug screening, tumor modeling, and creating implantable scaffolds for cancer treatment.

By manipulating cell arrangements and microenvironments, 3D bioprinting produces accurate cancer models. For the academic audience, this book blends bioengineering, medical insights, and real-world applications. It provides valuable case studies and developments in 3D cancer model creation, enhancing the understanding of oncogenesis, tumor progression, and therapy responses.

Key features

  • Examines cutting-edge methods in 3D bioprinting that revolutionize cancer care, including patient-specific tumor models and personalized treatments
  • Offers in-depth analysis of the creation and application of intricate tumor models, enhancing the accuracy of drug testing and treatment planning
  • Integrates bioengineering, medical insights, and real-world applications, making it a valuable resource for understanding the future of personalized cancer therapy

Readership

Academic professionals, including researchers, clinicians, and students in the fields of oncology, bioengineering, and medical sciences

Table of contents

1. An Overview of 3D Bioprinting in Cancer Therapy

1. An Overview of 3D Bioprinting in Cancer Therapy

2. 3D Bioprinted Cancer Models: Bridging Basic Biology and Drug Development

3. Advancing Anti-Cancer Therapy: The Role of Three-Dimensional (3D) Bioprinting

4. 3D Printing for Cancer Diagnosis and Treatment monitoring

5. 3D printing: Biological printing ink, printing method for Cancer Therapy

6. 3D Printing in Biomedicine: Transforming Personalized Cancer Care

7. 3D Bioprinting Technology for tumor Cell Modelling and Tumor Therapy

8. Biomaterials Integrated 3D Bioprinting: Transforming High-Throughput Drug Screening in Cancer Therapy

9. Tissue Engineering with 3D Bioprinting: Pioneering the Future of Cancer Therapy

10. Therapeutic Precision: Harnessing 3D Printing for Drug Delivery for Cancer Therapy

11. Combinational Gene Therapy for Cancer: Nanoplatform-Based Strategies and Principles

12. Gene Therapy and Bioprinting Synergy for cancer immunotherapy

13. Innovations in 3D Bioprinting: Shaping the Future of Cancer Biology and Precision Medicine

14. In silico techniques, artificial intelligence, and machine learning for 3D Bioprinting in Oncology

15. Clinical trials, regulatory frameworks, and ethical considerations surrounding 3D bioprinting in cancer treatment

16. Current and Future Perspective of 3D Bioprinting in Oncology

Product details

  • Edition: 1
  • Latest edition
  • Published: March 1, 2027
  • Language: English

About the editors

AK

Anand Krishnan

Dr. Anand Krishnan, Principal Investigator, Department of Haematology and Cell Biology, School of Pathology, Faculty of Health Sciences, University of the Free State, South Africa. He leads the Precision Medicine Integrative Nano Diagnostics (P-MIND) Research Lab, which focuses on the biological functions of extracellular vesicles (EVs) in synthetic biology. His research focuses on establishing an extracellular vesicle (EV) biofoundry by integrating synthetic biology. His research encompasses cell modification, therapeutic target, biomarker discovery from EVs derived from liquid biopsies, and the role of circulating biomarkers in disease development. Dr. Krishnan has authored over 150 articles and edited ten books published by Elsevier, Springer, and Wiley. He received the National Research Foundation (NRF) rating for Next Generation Researchers in South Africa. In the latest list published by Stanford University, Dr. Krishnan was named among the Top 2% of the most influential scientists worldwide. He is an active member of the International Society of Extracellular Vesicles (ISEV), the African Organization for Research and Training in Cancer (AORTIC), and the American Association of Cancer Research (AACR). Recently, he has been serving as an editor for the eLife journal, focusing on the Africa region.

Affiliations and expertise
Precision Medicine and Integrated Nano-Diagnostics (P-MIND) Research Group, Office of the Dean, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa

MS

Mamello Sekhoacha

Professor Mamello Sekhoacha is an Associate Professor of Pharmacology at the University of the Free State and a former Specialist Scientist at the South African Medical Research Council. She earned her Ph.D. in Pharmacology from the University of Cape Town. Her research tackles challenges of chemotherapy resistance and toxicity through the discovery of novel lead compounds, the development of targeted nano-delivery systems, molecular pharmacology, cancer pharmacogenetics, and precision oncology. Additionally, she is a qualified Clinical Research Associate (CRA) with expertise in Health Research Ethics and Governance.

Affiliations and expertise
Department of Pharmacology, Faculty of Health Sciences, University of the Free-State, Bloemfontein, South Africa

PM

Parks Makhoahle

Professor Parks Makhoahle is a distinguished member of the Golden Key International Honour Society. He earned his BSc in Microbiology and Biotechnology, B.Med.Sc Hons, and M.MedSc in Medical Microbiology and Virology from the University of Free State, along with a D.H.Sc in Biomedical Technology and a PGDIPHE from the Central University of Technology. Currently, he is pursuing a second doctorate in educational studies and serves as the interim Director of the Centre for Quality of Health and Living. His research focuses on the anti-cancer properties of natural products, genotoxicity, and preventing mycotoxin-induced carcinogenicity, collaborating with UFS, NHLS, and WHO-Lesotho. With over 30 peer-reviewed publications and a book chapter, he supervises nine master's students and two PhD candidates. He is also a registered medical biological scientist, a reviewer for NRF and a recipient of the multi-Vice-Chancellor’s Awards, contributing to the establishment of CUT’s advanced Biochemistry and Tissue Culture facility.

Affiliations and expertise
Department of Health ScienceCentral University of Technology Free-State, South Africa

AS

Arun Kumar Singh

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.

Affiliations and expertise
Assistant Professor, University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, Tehsil Kharar, Distt. Mohali, Punjab, India